Published:
InSet Technologies Appoints Jon Tremmel to its Board of Directors
InSet Technologies Appoints Jon Tremmel to its Board of Directors
MT. OLIVE, N.J., May 9 /PRNewswire/ -- InSet Technologies, an emerging
leader in the development of implantable drug infusion pumps for targeted
delivery of medications, announced today the addition of Jon Tremmel to its
Board of Directors.
Before retiring from Medtronic Inc. after nearly 30 years of service, Jon
held a number of senior leadership positions including President of the
Neurological Division, President of the Physio-Control Division, President of
the Tachyarrhythmia Management Division and President of the Interventional
Vascular Division.
"InSet Technologies has a very innovative product in clinical trials right
now, and I look forward to being part of this growing company," said Jon
Tremmel. "I have spent most of my career seeking technological solutions to
help patients manage chronic conditions. None is more important to me than
finding more effective methods to manage the debilitating conditions of
chronic pain."
Mr. Tremmel also has served as a key member of the Medtronic Senior
Management Operating Committee. He achieved a Masters Degree in Engineering
from Boston University and a MBA from the University of Minnesota. Jon
presently resides inMinneapolis, Minnesota, with his family and is an active
member of the Minnesota Zoo Board, in addition to various Board positions for
other companies.
"InSet has made substantial progress in the development of a new
generation of implantable drug infusion pump technologies. Jon brings a
wealth of business expertise that will contribute to our growth and enhance
value to our shareholders," said Steve Adler, President and CEO of Inset
Technologies. "We look forward to his contribution to our company at this
important time in our history."
About InSet
InSet Technologies Incorporated (www.insetinc.com) headquartered inMt.
Olive, NJ is a development-stage medical device company. Its first product,
the Prometra(R) programmable, implantable drug infusion pump is undergoing
clinical trials for the treatment of chronic pain. About 70 million people in
the United States live with chronic pain. Chronic pain costs the U.S. more in
lost productivity and treatment than heart disease and cancer combined.
CAUTION: Prometra(R) pumps are Investigational Devices, which have not
yet been approved by the FDA.
SOURCE InSet Technologies
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily NewsTags: Tags: Pharmaceuticals, Healthcare, Biotechnology, Health, new jersey
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
